Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy
Glen Le Flahec, Manon Briolais, Briac Guibourg, Gilles Lemasson, Jean-Luc Grippari, Francoise Ledé, Pascale Marcorelles, Arnaud Uguen
Journal of Clinical Pathology Feb 2020, 73 (2) 116-119; DOI: 10.1136/jclinpath-2019-206026